AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02818023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be given at 480 mg twice daily, 720 mg twice daily, or 960 mg twice daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib.
Study NCT02818023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be given at 20 mg once daily, 40 mg once daily, or 60 mg once daily. Treatment with cobimetinib will commence on the same day. Cobimetinib will be given daily for 21 days, then held for 7 days.
Study NCT03938766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSMA PET/CT
Description: Repeat PSMA PET/CT 4 weeks post initiation of clinically indicated ADT in patients with prior negative PSMA PET/CT performed for biochemical recurrence.
Study NCT02021617 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Intraosseous access
Description: The EZ-IO Intraosseous Vascular Access System (Vidacare Corporation, Shavano Park, TX, USA) has been cleared by the U.S. Food and Drug Administration, Health Canada, and the European Union for the administration of drugs and fluids anytime vascular access is difficult to obtain in emergent, urgent, or medically necessary cases. It consists of a driver-a small battery-powered drill-and a needle set designed for insertion into the IO space of the proximal tibia, distal tibia, or proximal humerus. Needles are 15 gauge and available in three lengths: 15 mm, 25 mm, and 45 mm. In this study the 45 mm EZ-IO needle set will be used for all humeral placements and the 25 mm needle set will be used for all tibial placements.
Study NCT00361868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate (F) + metformin (M) hydrochloride fixed combination
Description: First period: F80mg/M500mg - per os - twice a day during 2 weeks and F80mg/M850mg - per os - twice a day during 10 weeks - Second period: F54mg/M850mg - per os - three times a day during 12 weeks
Study NCT00361868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: First period: 4 mg - per os - daily during 12 weeks - Second period: 4 mg - per os - twice a day during 12 weeks
Study NCT04251299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based, mentored vegetable gardening program
Description: The mentored vegetable gardening program pairs each participant with a certified Master Gardener. The participant/Master Gardener dyads work together to plan, plant and tend to a vegetable garden at the participant's home throughout the year. Gardening supplies, plants and seeds are provided.
Study NCT00615225 — intervention group
Intervention type: PROCEDURE
Intervention: Muscle biopsy
Description: Muscle biopsies were taken through the operation site from the vastus lateralis thigh muscle at the beginning of surgery
Study NCT03777878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to oxytocin
Description: two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
Study NCT03075696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab will be administered at a dose and as per the schedule specified in the respective arms.
Study NCT00975585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: soft contact lens, 2-week replacement indicated
Study NCT00975585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: soft contact lens with a 4-week replacement indicated.
Study NCT02526576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stromal Vasular Fraction
Description: The stromal vascular fraction obtained from adipose tissue will be added to the graft
Study NCT03023579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The star excursion balance test
Study NCT04925076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
Study NCT04925076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A beverage that does not meaningfully increase breath alcohol concentration.
Study NCT01905345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training
Study NCT03086707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette
Description: After enrollment, and between Visit 2 and Visit 3, the subjects will abstain from smoking for a period of 8 hours. At Visit 3, after the 8-hour smoking abstinence period, the subjects will smoke 1 single cigarette.
Study NCT03075696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 mg single dose IV infusion on Day -7; or 2000 mg single dose administered on Day -7, or split into two 1000 mg doses administered on Days -1 and -7, and per the schedule specified in the respective arms.
Study NCT03075696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as an IV infusion, if required, for the management of severe Cytokine Release Syndrome (CRS) occurring during or after any infusion of glofitamab, as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.
Study NCT00097474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone will be given alone or in combination with Melatonin to see if symptoms of jet lag are alleviated
Study NCT00097474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin will be given alone or in combination with Hydrocortisone to see if symptoms of jet lag are alleviated
Study NCT00097474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03300154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: The study nurses will schedule an appointment with the doctor at the health center, within 4 weeks from the participant's inclusion in the study. Participants who attend the first visit at the health center will receive a direct incentive consisting of the payment of a limited amount to be determined (approximately AR $ 150-200) through a shopping voucher for the amount mentioned. Participants attending the follow-up visit at the health center within 3 months from their inclusion in the study will participate in a lottery. The lottery will offer the possibility of winning a new voucher with a probability of 1 in 3. Participants who do not attend the health center will not receive any incentive.
Study NCT03300154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Framing (SMS)
Description: After inclusion, participants will receive weekly text messages (SMS) using a specific framing or formulation of the message, highlighting the potential benefits and positive aspects of health care. These messages will promote follow-up visits, adherence to treatment, and benefits to be gained from a follow-up visit with the physician. Messages will be sent with a frequency of two per week during the first 30 days and then 1 per week until the end of the follow-up. These messages will have no cost to participants.
Study NCT02495259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZU-bend stylet
Description: Laryngoscopy and intubation after induction of anesthesia will be done using the GlideScope and the ZU-bend stylet. The ZU-bend is a specific shaping technique of the intubating stylet that is closely related to the GlideScope blade curvature. Zu-bend stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
Study NCT02495259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GlideScope
Description: Laryngoscopy and intubation after induction of anesthesia will be done using the the GlideScope technique. The GlideScope is a video laryngoscope that provides a real-time view of the airway and tube placement during intubation. GlideScope is removed after DLT is in the trachea, and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
Study NCT02495259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: Laryngoscopy and intubation after induction of anesthesia will be done using the the GlideScope technique. The GlideScope is a video laryngoscope that provides a real-time view of the airway and tube placement during intubation. GlideScope is removed after DLT is in the trachea, and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
Study NCT02495259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GlideRite stylet
Description: Laryngoscopy and intubation after induction of anesthesia will be done with the GlideScope using the GlideRite stylet. The GlideRite stylet is specifically designed to work with the GlideScope and provides the necessary rigidity and curvature to an otherwise flexible tube. GlideRite stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
Study NCT02495259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh blade
Description: Direct laryngoscopy and intubation after induction of anesthesia will be done with the Macintosh blade and a regular double-lumen endobronchial tube (DLT) stylet. The Macintosh blade is used to facilitate visualization of the larynx during double or single lumen endobronchial tube placement. After intubation the Macintosh laryngoscope is removed and the confirmation of the successful placement of the double-lumen endobronchial tube in done in the standard fashion.
Study NCT02495259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular Double-lumen endobronchial tube (DLT) Stylet
Description: Direct laryngoscopy and intubation after induction of anesthesia will be done with a regular double-lumen endobronchial tube (DLT) stylet and the Macintosh blade. The DLT stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, Macintosh laryngoscope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
Study NCT04462211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of management pharmacological protocol of constipation
Description: first 48 hours:~* polyethylene glycol 3350 (about 17 grams) 1 every 8 hours enterally.~* Patients who have vomiting and / or gastric residue greater than 500 mL (in a timely measurement every 6 hours) will also be given domperidone 10 mg every 8 hours intravenously.~* Patients who have excessive abdominal distension will be administered in addition, levosulpiride 25 mg every 8 hours intravenously.~  48 hour evaluation:~* Patients who do not have bowel movements will be administered lactulose or sodium phosphate enema.~* For patients who do not have a bowel movement, administration of neostigmine intravenously or of naloxone enterally will be evaluated.~* Every patient who uses one or more prokinetics will have an electrocardiogram.~* Any patient who has bowel movements during management, doses of polyethylene glycol 3350 will be adjusted according to the daily goal of bowel movements, the days of treatment of the prokinetics will be adjusted, for a maximum of 5 consecutive days.
Study NCT04462211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of bundle of prevention and non-pharmacological management
Description: Bundle of prevention:~* Start early enteral nutrition.~* Optimize and / or decrease opioid doses.~* Start early mobilization.~Non-pharmacological management bundle~* Select laxative and/or prokinetic/s to manage constipation.~* Optimize and / or decrease doses of opioids and sedatives.~* Start early mobilization.~* Pharmacological reconciliation.
Study NCT01931696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Description: 100 patients receive verum acupuncture treatment once every other day,choosing Dazhui(GV14), Fengmen(BL12), Feishu(BL13), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive verum acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
Study NCT01931696 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: 100 patients receive sham acupuncture treatment once every other day, choosing Jinsuo(DU08), Ganshu(BL18), Danshu(BL19), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive sham acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
Study NCT03703869 — intervention group
Intervention type: DRUG
Intervention: Insulin glargine (U300)
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection
Study NCT02516943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The patient's ABGs were test according to a 4 - hour routine
Study NCT02516943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guideline
Description: The patient's ABGs were test according to the guideline for requests Arterial Blood Gas status post cardiac surgery
Study NCT00797472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-mabHD
Description: An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
Study NCT04074616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Dose
Description: Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks,with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used.
Study NCT04074616 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Low dose
Description: Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes
Study NCT03294720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bio-ACL
Description: ACL reconstruction with either hamstring or patellar autograft, wrapped in amion collagen wrap, and stem cells from bone marrow aspirate.
Study NCT03294720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: amnion wrap and BMAC
Description: amnion collagen wrap and bone-marrow aspirate in ACL reconstruction autograft
Study NCT01539018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
Study NCT01539018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib plus tegafur-uracil
Description: Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity and TEGAFUR-URACIL 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
Study NCT00797472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD
Description: A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.
Study NCT00602953 — intervention group
Intervention type: OTHER
Intervention: No intervention planned.
Description: This is a cross-sectional observational study, no intervention is planned.
Study NCT04465331 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: completion of Exercise Adherence Rating Scale (EARS)
Study NCT02233816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose of quadrivalent VLP vaccine
Description: A single low dose of quadrivalent VLP vaccine
Study NCT02233816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dose of quadrivalent VLP vaccine
Description: A single medium dose of quadrivalent VLP vaccine
Study NCT02233816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose of quadrivalent VLP vaccine
Description: A single high dose of quadrivalent VLP vaccine
Study NCT02233816 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo
Study NCT02122393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Study NCT04621825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActivHeal Silicone PHMB Foam Adhesive and Non Adhesive dressing.
Description: Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over a four - six-week period (per AMS Product) or until the wound is healed to extent that the use of the ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings. is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection.
Study NCT04073290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 550 milligram Oral Tablet [XIFAXAN]
Description: Rifaximin 550 milligram b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
Study NCT04073290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
Study NCT04073290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactulose 667 milligram/milliliter Oral Solution
Description: Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS
Study NCT04073290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose 667 milligram/milliliter Oral Solution
Description: Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS
Study NCT04544969 — intervention group
Intervention type: DRUG
Intervention: cisplatin-based chemotherapy
Description: GP: cisplatin 80 mg/m2 intravenous infusion on day1, gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8, both drugs are given every 3 weeks, recommended 6 cycles.~TP: cisplatin 75 mg/m2 intravenous infusion in day1, docetaxel 75 mg/m2 intravenous infusion in day 1, both drugs are given every 3 weeks, recommended 6 cycles.~PF: cisplatin 100 mg/m2 intravenous infusion in day1, fluorouracil 4000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~TPF: cisplatin 60 mg/m2 intravenous infusion in day1, docetaxel 60 mg/m2 intravenous infusion in day 1, fluorouracil 3000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~Choice of chemotherapy regimen is decided by patient's doctor in charge.
Study NCT02728557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive-Expressive Therapy
Description: Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
Study NCT02728557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Therapy
Description: Supportive psychotherapy for depressive disorder for 16 weeks.
Study NCT01718743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT01718743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01718743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03516708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Drug provided.
Study NCT03516708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiation therapy
Description: Short-course pelvic radiation therapy, 5 Gy x 5 fractions over 1 week
Study NCT03516708 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Short-course radiation therapy
Description: Short-course pelvic radiation therapy, 5 Gy x 5 fractions over 1 week
Study NCT03871309 — intervention group
Intervention type: DEVICE
Intervention: Tigertriever
Description: Mechanical Thrombectomy
Study NCT03526393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Survey training equipment
Description: The survey was checking the equipment designed to assist the lifter training survey with greater precision, in aspects of average height of contact of the ball by striker and maximum perimeter of contact with the ball, for the execution of the attack.
Study NCT03526393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Attack and serve training equipment
Description: The attack and serve training equipment was designed to assist the athlete in their body positioning for the execution of the fundamentals of the attack and serve, and the correct extension execution of the of trunk, upper limbs and reaction time of contact with the ball.